Stronger Net Interest Income Guidance and No Buybacks Could Be A Game Changer For Associated Banc-Corp (ASB)

Associated Banc-Corp

Associated Banc-Corp

ASB

0.00

  • In July 2026, Associated Banc-Corp reported second-quarter results showing net interest income rising to US$370.04 million and net income to US$123.56 million, alongside higher net charge-offs of US$23.20 million and no share repurchases during the period under its various buyback authorizations.
  • The company also issued 2026 guidance calling for net interest income growth of 19% to 21% versus 2025 standalone results, highlighting the earnings impact of its American National acquisition while refraining from deploying additional capital into buybacks this quarter.
  • We’ll now examine how this higher net interest income guidance, underpinned by the American National acquisition, may influence Associated Banc-Corp’s investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Associated Banc-Corp Investment Narrative Recap

To own Associated Banc-Corp, you need to be comfortable with a regional bank leaning into higher-yielding commercial relationships while managing a rising credit risk profile. The latest quarter supported this earnings-focused narrative through higher net interest income and net income, but the jump in net charge-offs underlines that credit quality remains the most important near-term risk. The higher 2026 net interest income guidance does not materially change that near-term risk focus for shareholders.

The new 2026 guidance for 19% to 21% net interest income growth versus 2025 standalone results is the clearest tie-in to this quarter’s story. It reinforces how the American National acquisition is feeding into higher interest income at a time when the bank is choosing not to add buybacks, keeping more capital available to absorb potential credit losses and support balance sheet resilience around its key lending catalysts.

Yet beneath the stronger net interest income, investors should still be aware of the rising net charge-offs and what they could mean for...

Associated Banc-Corp's narrative projects $2.2 billion revenue and $696.2 million earnings by 2029. This requires 11.8% yearly revenue growth and about a $204.9 million earnings increase from $491.3 million.

Uncover how Associated Banc-Corp's forecasts yield a $33.56 fair value, a 10% upside to its current price.

Exploring Other Perspectives

ASB 1-Year Stock Price Chart
ASB 1-Year Stock Price Chart

Two fair value estimates from the Simply Wall St Community span roughly US$33.56 to US$50.52 per share, showing a wide spread in expectations. Against that backdrop, the recent increase in net charge-offs and credit loss risk gives you a concrete issue to test your own view on Associated Banc-Corp’s future performance and invites you to weigh several alternative viewpoints.

Explore 2 other fair value estimates on Associated Banc-Corp - why the stock might be worth just $33.56!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Associated Banc-Corp research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Associated Banc-Corp research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Associated Banc-Corp's overall financial health at a glance.

No Opportunity In Associated Banc-Corp?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

  • Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
  • Find 51 companies with promising cash flow potential yet trading below their fair value.
  • AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.